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Abstract 
Background: Diabetes therapy that not only lowers glucose levels but also lengthens life spans is required. We 
previously demonstrated that DPP-4 inhibition ameliorated β cell apoptosis and adipose tissue inflammation in β cell-
specific glucokinase haploinsufficient mice fed a diet containing a combination of sucrose and linoleic acid (SL).
Methods: In this study, we investigated the effects of DPP-4 inhibition in obese diabetic db/db mice fed an SL diet 
or a control diet containing sucrose and oleic acid (SO). We also examined the effects of DPP-4 inhibition in IRS-1-defi-
cient mice fed an SL or SO diet as a model of insulin resistance.
Results: DPP-4 inhibition efficiently increases the active GLP-1 levels in db/db mice. Unexpectedly, the SL diet, but 
not the SO diet, markedly increases mortality in the db/db mice. DPP-4 inhibition reduces the early lethality in SL-fed 
db/db mice. DPP-4 inhibition improves glucose tolerance, β cell function, and adipose tissue inflammation in db/db 
mice fed either diet. No significant changes in glycemic control or β cell mass were observed in any of the IRS-1-defi-
cient mouse groups.
Conclusions: A diet containing a combination of sucrose and linoleic acid causes early lethality in obese diabetic db/
db mice, but not in lean and insulin resistant IRS-1 knockout mice. DPP-4 inhibition has protective effects against the 
diet-induced lethality in db/db mice.
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Background
Accumulating evidence suggests that diabetic patients 
have a decreased life span, compared with non-diabetic 
subjects [1, 2]. Therefore, promoting longevity is one of 
the definitive goals for the cure and care of diabetes. The 
activation of insulin signaling is a major approach for 
blood glucose-lowering therapy, while the loss of insulin 
receptor-mediated signaling has resulted in extensions 
of the life spans in several models [3, 4]. Dietary sugar 
and fat intake influences not only metabolism in various 
metabolic tissues, but also aging [5]. However, the effects 
of dietary fatty acids or diabetes therapy on life span in 
diabetic patients remain obscure.
Palmitic acid, oleic acid, and linoleic acid are the three 
major fatty acids among plasma lipids [6]. We previously 
investigated diet-induced metabolic changes in β cell-
specific glucokinase haploinsufficient (βGck+/−) diabetic 
mice fed a diet containing a combination of sucrose and 
oleic acid (SO) or sucrose and linoleic acid (SL) [7, 8]. SL 
induced β cell apoptosis and adipose tissue inflamma-
tion in βGck+/− mice. βGck+/− mice exhibit impaired 




*Correspondence:  jshira-tky@umin.ac.jp; terauchi-tky@umin.ac.jp 
1 Department of Endocrinology and Metabolism, Graduate School 
of Medicine, Yokohama-City University, 3-9 Fukuura, Kanazawa-ku, 
Yokohama 236-0004, Japan
Full list of author information is available at the end of the article
Page 2 of 13Shirakawa et al. Diabetol Metab Syndr  (2016) 8:16 
insulin sensitivity. In Zucker fatty (fa/fa) rat, a model of 
obesity and insulin resistance, SL diet showed β cell fail-
ure, enhanced macrophage infiltration in adipose tis-
sue, and an elevated plasma tumor necrosis factor-α 
concentration compared with SO diet [9]. These results 
inspired us to investigate the impacts of SL and SO diets 
on metabolic tissues in obese diabetes model mice. We 
also reported that treatment with a dipeptidyl pepti-
dase-4 (DPP-4) inhibitor ameliorated SL diet-induced 
β cell apoptosis and adipose tissue inflammation in 
βGck+/− mice [7, 8]. DPP-4 inhibitors induced increases 
in active incretins (GLP-1 and GIP) and other circulating 
peptides by slowing enzymatic cleavage, thereby enhanc-
ing incretin-induced glycemic control. A number of pre-
clinical studies have also suggested the possibility that 
GLP-1 receptor agonists and DPP-4 inhibitors exhibit 
pleiotropic metabolic actions, such as cardioprotection 
[10, 11]. A meta-analysis of randomized clinical trials 
suggested that DPP-4 inhibitors reduced cardiovascular 
events and all-cause mortality in patients with type 2 dia-
betes with a mean follow-up period of 44.1  weeks [12]. 
In an aged, high-fat-diet-induced obesity mouse model, 
the survival rates were improved by chronic DPP4 inhi-
bition [13]. However, the EXAMINE and SAVOR-TIMI 
53 phase III/IV trials showed no significant differences 
in cardiovascular events between DPP-4 inhibitors and 
a placebo in type 2 diabetic patients [14, 15]. Hence, the 
effect of DPP-4 inhibition on longevity has remained 
controversial.
Obese diabetic db/db mice are morbidly obese and 
exhibit severe insulin resistance, hyperglycemia, and 
diabetic complications [16, 17]. High-fat-diet-loading 
reportedly shortens the life span of db/db mice [18]. 
In the present study, we examined the effects of DPP-4 
inhibitors on glucose tolerance, β cell loss, and adipose 
tissue inflammation in obese diabetic db/db mice fed an 
SL or SO diet. Although both of these diets contained 
similar ratios of fat and saturated fatty acids, the SL diet 
increased the mortality rate of db/db mice. Interestingly, 
DPP-4 inhibition enabled a nearly complete restora-
tion of the mortality rate in SL-fed db/db mice. We also 
assessed the effects of DPP-4 inhibition in IRS-1 deficient 




Animal study was carried out in strict accordance with 
the recommendations in the Guide for the Care and Use 
of Laboratory Animals of the Yokohama City Univer-
sity. The protocol was approved by the Yokohama City 
University Institutional Animal Care and Use Commit-
tee (IACUC) (Permit Number: 11-29, F-A-13-043). All 
experiments were performed under appropriate anesthe-
sia, and all efforts were made to minimize suffering.
Littermate db/db and db/+ mice aged 7  weeks were 
purchased from Charles River Japan (Yokohama, Japan). 
We backcrossed IRS-1−/− mice with C57Bl/6J mice more 
than 10 times [19]. The mice were fed a standard-chow 
diet (MF, Oriental Yeast, Japan) until 8 weeks of age and 
then were given free access to the experimental diets. All 
the experiments were conducted on male littermates. 
Animal housing rooms were maintained at a constant 
room temperature (25  °C) and a 12-h light (7:00 a.m.)/
dark (7:00 p.m.) cycle. In the survival study, mice were 
monitored two times a day for clinical signs as described 
in the Yokohama City University Institutional Animal 
Care and Use Committee (IACUC) policy to categorize 
animals as morbid or moribund. Mice were sacrificed 
when distress was apparent as defined by our IACUC 
approved animal protocol (hunched posture, reduced 
activity, altered respiratory pattern such as abdominal 
breathing, severe weight loss, or inability to stand). Ani-
mals judged to be moribund were euthanatized with an 
anesthesia (mixture of medetomidine hydrochloride, 
midazolam, and butorphanol tartrate) and counted 
as lethality. At the end of these experimental proce-
dures, the remaining mice were also euthanized with an 
anesthetics.
Diets
The compositions of the SO and SL diets are described 
in Additional file 1: Table S1 [7, 8]. The fat component of 
the SO and SL diets was derived from safflower oil and 
high-oleic sunflower oil blended with perilla oil, respec-
tively. The two diets were identical except for the type of 
fat used: oleic acid was used in the SO diet, and linoleic 
acid was used in the SL diet. Both diets contained similar 
amounts of palmitic acids. The experimental diets were 
freshly prepared weekly. A DPP-4 inhibitor des-fluoro-
sitagliptin (DFS) was administered orally by premixing 
with SO or SL to a concentration of 0.4 % [20]. Another 
DPP-4 inhibitor, MK-0626, was administered orally by 
premixing with SO or SL to a concentration of 0.0045 % 
[21]. Both the DFS and the MK-0626 used in this study 
were provided by Merck & Co., Inc.
Biochemical parameters
The blood glucose levels were determined using a Glut-
est Neo Super, Glutest Mint (Sanwa Chemical Co., 
Japan) or Glucose Assay Kit (BioVision, CA). Serum 
insulin levels and the triglyceride content in the liver 
were determined using an insulin kit (Morinaga, Japan) 
and the Determiner-L TG II kit (Wako Pure Chemical 
Industries, Japan), respectively. The levels of plasma ala-
nine aminotransferase, free fatty acid, total cholesterol, 
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and triglyceride were assayed using enzymatic methods 
(Wako Pure Chemical Industries). Serum DPP-4 activ-
ity was measured using a DPP4 Activity Assay Kit (Bio 
Vision, CA). Active GLP-1 was assayed using a Gluca-
gon-Like Peptide-1 (Active) ELISA Kit (Millipore, MA). 
An insulin tolerance test (ITT) was performed by intra-
peritoneally injecting mice with human insulin (1.5 mU/g 
body weight). An oral glucose tolerance test (OGTT) 
was performed by withholding all food from the mice for 
more than 18 h and then orally loading the mice with glu-
cose (1.5 mg/g body weight).
Histological analysis
Formalin-fixed, paraffin-embedded pancreas or adi-
pose tissue sections were immunostained with antibod-
ies to insulin (Santa Cruz, sc-9168), glucagon (Abcam, 
ab10988), or F4/80 (Serotec, MCA497). Biotinylated sec-
ondary antibodies, a VECTASTAIN elite ABC kit, and a 
DAB substrate kit (VECTOR) were used to examine the 
sections using bright-field microscopy, and Alexa Fluor 
488- and 555-conjugated secondary antibodies (Invit-
rogen) were used for fluorescence microscopy. All the 
images were acquired using a BZ-9000 microscope (Key-
ence) or a Carl Zeiss LSM 510 confocal laser-scanning 
microscope. The percent area of the pancreatic tissue 
occupied by the β cells was calculated using BIOREVO 
software (Keyence), as described previously [22]. More 
than five tissue sections from each animal, including rep-
resentative sections of each tissue region, were analyzed.
Real‑Time PCR
Tissue specimens were preserved in RNAlater reagent 
(QIAGEN) until the isolation of the total RNA. Total 
RNA was isolated from the epididymal fat using an 
RNeasy Lipid tissue kit (QIAGEN). cDNA was prepared 
using the TaqMan reverse transcriptase kit (Applied 
Biosystems) and was subjected to quantitative PCR 
using TaqMan Gene Expression Assays (7900 real-time 
PCR system; Applied Biosystems) with THUNDER-
BIRD qPCR Master Mix (TOYOBO). Transcription of 
each gene was detected using TaqMan Gene Expression 
Assays (Thermo Fisher Scientific Inc.): F4/80 (Adgre1, 
Mm00802529_m1), CD11c (Itgax, Mm00498698_
m1), TNF-α (Tnf, Mm00443258_m1), MCP-1 (Ccl2, 
Mm00441242_m1), and PAI-1 (Serpine2, Mm00436753_
m1). The data was normalized according to the β-actin 
(Actb, Mm02619580_g1). Each quantitative reaction was 
performed in duplicate.
Statistical analyses
All the data are expressed as the mean ± S.E. and were 
analyzed using an ANOVA. Differences were considered 
significant if the P value was <0.05 (*, †).
Results
A single oral dose of DPP‑4 inhibitors sufficiently 
suppressed DPP‑4 activity in db/db mice
To assess the effects of DPP-4 inhibitor in db/db mice 
fed an SL or SO diet (Additional file 1: Table S1), we per-
formed an oral meal tolerance test (12 mg/g body weight) 
in 8-week-old db/+ or db/db mice. The DPP-4 inhibitors 
des-fluoro-sitagliptin (DFS) and MK-0626 were sepa-
rately premixed with SO or SL at a concentration of 0.4 
or 0.0045 %, respectively. DPP-4 is thought to be an adi-
pokine that is released from adipose tissue at a higher 
level in obese individuals [23]. However, the DPP-4 activ-
ities were similar between the db/+ mice and the db/db 
mice fed an SO or SL diet (Fig.  1a). DFS and MK-0626 
similarly inhibited the serum DPP-4 activity by approxi-
mately 80 % in db/db mice fed an SL or SO diet (Fig. 1a). 
We next measured the serum active GLP-1 concentration 
after oral loading with an SO or SL meal (12 mg/g body 
weight) in the presence or absence of a DPP-4 inhibitor in 
standard-chow diet-fed db/+ or db/db mice. The results 
showed no significant differences in serum active GLP-1 



















db/db SL + DFS
db/db SL + MK-0626
db/db SO
db/db SO + DFS





















db/db SL + DFS
db/db SL + MK-0626
db/db SO
db/db SO + DFS










Fig. 1 Changes in serum DPP-4 activity and active GLP-1 concentra-
tions in db/+ mice and db/db mice during an oral meal tolerance 
test. The experiments were performed in db/+ or db/db mice fed 
an SL diet, an SO diet, or a diet containing the DPP-4 inhibitor 0.4 % 
des-fluoro-sitagliptin or 0.0045 % MK-0626. a Serum DPP-4 activity 
was measured in mice fed the indicated diets ad libitum (n = 5). 
*P < 0.05 vs. db/db SL. †P < 0.05 vs. db/db SO. b Serum active GLP-1 
concentration at 0 min (fasted > 20 h), 30, and 120 min after the oral 
administration of each diet test meal (12 mg/g body weight) in db/+ 
mice and db/db mice that had been fed either the SO or SL diet 
(n = 3–4). To obtain a sufficient amount of whole blood to measure 
the biologically active form of GLP-1, blood was collected from the 
inferior vena cava with a DPP-4 inhibitor (Millipore) at the time points 
indicated. *P < 0.05 vs. db/db SL. †P < 0.05 vs. db/db SO
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mice or db/db mice at 0, 30, or 120  min after feeding 
(Fig.  1b). The serum active GLP-1 concentrations were 
significantly increased by DPP-4 inhibition with DFS or 
MK-0626 in db/db mice fed an SO or SL diet (Fig.  1b). 
Thus, DFS and MK-0626 efficiently inhibited the DPP-4 
activity and increased the active GLP-1 levels in db/db 
mice. We previously reported that DFS improved β cell 
ER stress, adipose tissue inflammation, and hepatic stea-
tosis in lean diabetic βGck+/− mice [7, 8]. Hence, we used 
DFS as the DPP-4 inhibitor for the db/db mouse model in 
this study.
Sucrose‑ and linoleic acid‑diet‑induced early mortality 
in db/db mice and reduction in lethality by DPP‑4 
inhibition
Db/+ mice and db/db mice fed an SL diet or an isocaloric 
SO diet for 8 weeks were evaluated for glucose tolerance 
and phenotypic changes in metabolic tissues (Fig. 2). To 
evaluate the effect of a DPP-4 inhibitor as a treatment 
for diet-induced metabolic dysfunction in obese diabetic 
mice with severe insulin resistance, we also performed 
an 8-week study comparing db/db mice fed a diet con-
sisting of SL or SO plus DPP-4 inhibitor (Fig. 2). Unex-
pectedly, early lethality at 1–2  months after the start of 
the experiments was observed in the SL-fed db/db mice, 
but not in the SO-fed mice or db/db mice (Fig. 3). Over 
70 % of the db/db mice died after 5–8 weeks of SL-load-
ing. In contrast, db/db mice fed an SL + DPP-4 inhibitor 
diet exhibited more than 80 % survival at the end of the 
experiment period (Fig.  3). We performed three inde-
pendent 8-week meal loading tests and combined these 
results (Additional file 2: Figure S1). No apparent signs of 
injury or infection were observed in the dead SL-fed db/
db mice. We also confirmed that none of the db/db mice 
fed a standard chow diet died before 16 weeks of age.
No significant changes in insulin sensitivity and glucose 
tolerance between SL‑fed db/db mice and SO‑fed db/db 
mice and improvement induced by DPP‑4 inhibitor
Compared with the db/+ mice, the db/db mice showed an 
increased body weight, liver weight, epididymal fat weight, 
blood glucose level, insulin resistance, and glucose intol-
erance after feeding with either the SL or SO diet (Fig. 4a–
d; Additional file 3: Figure S2). No significant differences 
in body weight, liver weight, blood glucose level, insulin 
sensitivity, glucose tolerance, or insulin secretion after 
glucose loading were observed between the SO group and 
the SL group for either genotype (Fig.  4a–e; Additional 
file 3: Figure S2). Treatment with the DPP-4 inhibitor had 
no significant effect on body weight gain, liver weight, or 
epididymal fat weight in db/db mice fed an SL or SO diet 
(Fig.  4a; Additional file  3: Figure S2). The blood glucose 
levels were decreased by the addition of the DPP-4 inhibi-
tor to the diets until the second week of the experiment 
in both groups (Fig. 4b). After the manifestation of severe 
hyperglycemia in the db/db mice fed an SL or SO diet, 
treatment with the DPP-4 inhibitor was no longer capa-
ble of reducing the blood glucose levels (Fig.  4b). How-
ever, DPP-4 inhibition significantly decreased the blood 
glucose levels at 90 or 120 min in an insulin tolerance test 
and at 30 min in an oral glucose tolerance test in db/db 
mice after SL or SO feeding for 8 weeks (Fig. 4c, d). The 
blood glucose levels at 60, 90, 120 min during glucose tol-
erance test showed values over the limit of detection of 
the glucometers in db/db mice fed an SL or SO diet, but 
not in DPP-4 inhibitor-treated db/db mice. Furthermore, 
the fasting serum insulin levels were significantly elevated 
in DPP-4 inhibitor-treated db/db mice in both diet groups 
(Fig. 4e). These results indicated that the DPP-4 inhibitor 
provided a slight but significant improvement in insulin 
sensitivity and glucose tolerance, even in obese hypergly-
cemic db/db mice fed an SL or SO diet.
DPP‑4 inhibitor protected against β cell failure in db/db 
mice fed an SL or SO diet
SL significantly reduced the β cell mass and the β cell 
proportion in islet cells through a greater increase in 
apoptosis, compared with that induced by SO, in lean 
diabetic βGck+/− but not wild-type mice [7]. Obese dia-
betic db/db mice fed a normal chow diet showed a tran-
sient increase in β cell mass and proliferation from 1 to 
3 months of age, followed by a subsequent decrease with 
further aging [24]. To analyze the effects of the SL and 
SO diets on β cell loss in db/db mice, we investigated the 
β cell mass and the β cell proportion in islet cells in SL- 
or SO-diet-fed 14-week-old db/db mice (Fig. 2). No sig-
nificant changes in β cell mass or β cell proportion were 
observed between the SL and SO groups in both db/+ 
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Fig. 2 Experimental protocol. Both the db/+ and db/db mice were 
fed a standard chow diet until 8 weeks of age and were then given 
free access to the experimental diets. Experiments were performed 
on db/+ and db/db mice after 8 weeks on the SL diet, SO diet, 
SL + DPP-4 inhibitor (0.4 % des-fluoro-sitagliptin) diet, or SO + DPP-4 
inhibitor (0.4 % des-fluoro-sitagliptin) diet
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Fig. 3 SL-diet-induced early mortality in db/db mice and DPP-4 inhibition reduced lethality. Survival rates of indicated mice (n = 27). The db/+ and 
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Fig. 4 DPP-4 inhibitor improved insulin sensitivity and glucose tolerance in SL- or SO-fed db/db mice. The experiments were performed in 
16-week-old mice, as shown in Fig. 2 (n = 6–11). a Body weight gain. b Blood glucose levels. *P < 0.05 vs. db/db SL. †P < 0.05 vs. db/db SO. c Blood 
glucose levels during insulin tolerance test (ITT). *P < 0.05 vs. db/db SL. †P < 0.05 vs. db/db SO. d Blood glucose levels during oral glucose tolerance 
test (OGTT). *P < 0.05 vs. db/db SL. †P < 0.05 vs. db/db SO. e Serum insulin levels during OGTT. *P < 0.05 vs. db/db SL. †P < 0.05 vs. db/db SO
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β cells in the islets was observed in db/db mice fed an SL 
or SO diet, compared with db/+ mice (Fig.  5a, c). The 
β cell mass and islet morphology in SL- or SO-fed db/
db mice were similar to those observed in normal chow-
fed db/db mice of the same age (data not shown). These 
results suggested that the influence of the difference in 
the SL and SO diets was less than that of the intrinsic 
mechanism responsible for β cell loss in db/db mice.
We previously demonstrated that DPP-4 inhibition 
ameliorated β cell ER stress and apoptosis in SL-fed 
βGck+/− mice, and the GLP-1 receptor agonist liraglu-
tide protected against reductions in β cells in neonatal 
βGck−/− mice independent of insulin secretion [7, 25]. As 
expected, the treatment of SL- and SO-fed-db/db mice 
with a DPP-4 inhibitor for 8  weeks produced a signifi-
cant increase in β cell mass (Fig. 5b) and the relative β cell 
mass as a proportion of the total α-cell-plus-β-cell mass 
(Fig. 5d); furthermore, the abnormal distribution of pan-
creatic α cells was also corrected (Fig. 5c). The intensity 
of the fluorescence signals of insulin was also augmented 
by DPP-4 inhibition in db/db mice (Fig. 5c). Thus, DPP-4 
inhibition ameliorated β cell failure in db/db mice regard-
less of whether the mice were fed an SL or SO diet.
Inflamed adipose tissue was mitigated by DPP‑4 inhibition 
in db/db mice fed an SL or SO diet
Inflammation induced by the infiltration of macrophages 
or other hemocytes into adipose tissue contributes to obe-
sity-related insulin resistance in db/db mice [26]. Com-
pared with SO, SL increased CD11c+ M1 macrophage 
infiltration into visceral adipose tissue in βGck+/− mice 
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Fig. 5 DPP-4 inhibitor increased β cell mass and ameliorated islet morphology in SL- or SO-fed db/db mice. The experiments were performed 
in 14-week-old mice, as shown in Fig. 2. a Representative pancreatic sections stained with antibodies for insulin (brown) are shown. The scale bar 
represents 100 μm. b β cell mass (n = 6–8). The β cell area is shown as a proportion of the area of the entire pancreas. c Representative pancreatic 
sections stained with antibodies for insulin (green) and glucagon (red) are shown. The scale bar represents 50 μm. d Quantification of β cell mass as a 
proportion of the total α-cell-plus-β-cell mass in the islet (n = 6). *P < 0.05 vs. db/db SL. †P < 0.05 vs. db/db SO
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SL- or SO-fed db/db mice. The adipocyte area in db/db 
mice fed an SL or SO diet was larger than that in SL or SO 
diet-fed db/+ mice (Fig. 6a, b). An immunohistochemical 
analysis revealed that the proportion of F4/80+ crown-like 
structures (CLSs) in adipocytes was also increased in db/
db mice compared with db/+ mice, in both the SL and SO 
groups (Fig. 6c, d). The mRNA expression levels of F4/80, 
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Fig. 6 Inflamed adipose tissue was improved by DPP-4 inhibition in db/db mice fed an SL or SO diet. The experiments were performed in 14-week-
old mice, as shown in Fig. 2. a Representative histogram of adipocyte size in epididymal fat. b Average size of adipocyte from indicated mice (n = 5). 
c Epididymal fat tissue was stained with anti-F4/80 antibody. d The number of F4/80+ crown-like structures (CLSs) was counted as described in the 
Methods (n = 5). *P < 0.05 vs. db/db SL. †P < 0.05 vs. db/db SO. e, f Assessment of the levels of expression of the indicated mRNAs in epididymal fat 
as determined using real-time quantitative RT-PCR and normalization to the β-actin mRNA level (n = 5). *P < 0.05 vs. db/db SL. †P < 0.05 vs. db/db 
SO
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higher among the db/db mice fed an SL or SO diet 
(Fig. 6e, f ). No significant changes in the adipocyte area, 
the number of F4/80+ CLSs, inflammatory gene expres-
sions, or serum lipid parameters were observed between 
the SL and SO groups in the db/db or db/+ mice (Fig. 6a–
f; Additional file 4: Figure S3). These results indicated that 
adipose tissue inflammation was not caused by the dif-
ference in the compositions of the diets that were used 
to feed the mice. In fact, we also confirmed that db/db 
mice of the same age that were fed a standard diet showed 
F4/80+ CLSs and inflammatory gene expressions in adi-
pocytes to a similar degree as that observed in db/db mice 
fed an SL or SO diet (data not shown).
In SL-fed βGck+/− mice, DPP-4 inhibition averts adi-
pose tissue inflammation by reducing the infiltration of 
CD11c+ M1 macrophages and CD8+ T cells [8]. To evalu-
ate the use of a DPP-4 inhibitor as a treatment for adipose 
tissue inflammation in obese diabetic db/db mice with SL 
or SO, we examined visceral adipose tissue inflammation 
in DPP-4 inhibitor-treated db/db mice. The epididymal fat 
weight and lipid parameters in the SL- or SO-fed db/db 
mice were not affected by the addition of a DPP-4 inhibitor 
to the diet (Additional files 3 and 4: Figures S2 and S3). The 
adipocyte size tended to be decreased by the treatment 
with DPP-4 inhibitor in these mice (Fig.  6a, b). DPP-4 
inhibitor attenuated the proportion of F4/80+ CLSs and 
macrophage-related inflammatory gene expressions in the 
adipocytes of db/db mice in both diet groups (Fig. 6c–f).
We previously demonstrated that treatment with a 
DPP-4 inhibitor improved hepatic steatosis in both SL-
fed and SO-fed βGck+/− mice [8]. However, no signifi-
cant differences in the hepatic triglyceride contents were 
observed in SL- or SO-fed db/db mice in the presence or 
absence of a DPP-4 inhibitor (Additional file 5: Figure S4).
No significant effects of an SL or SO diet and DPP‑4 
inhibition in insulin‑resistant IRS‑1‑deficient mice
In db/+ or db/db mice, differential effects of an SL or SO 
diet on glucose metabolism were not observed (Figs. 4, 5, 6) 
[8]. An SL diet aggravated β cell function and adipose tissue 
inflammation in lean βGck+/− mice with impaired insulin 
secretion in response to glucose and normal insulin resist-
ance, compared with an SO diet [7, 8]. An SL diet, but not 
an SO diet, shortened the life spans of obese diabetic db/
db mice with severe insulin resistance (Fig. 3). To assess the 
impact of an SL or SO diet under an insulin-resistant state, 
we used an SL or SO diet with or without a DPP-4 inhibi-
tor to feed wild-type (WT) mice and insulin receptor sub-
strate (IRS)-1-deficient (IRS-1−/−) mice for 27 weeks. The 
IRS-1−/− mice showed normal glucose tolerance, periph-
eral insulin resistance (especially in skeletal muscle), com-
pensatory β cell mass hyperplasia, and growth retardation 
[19]. The body weight and blood glucose levels were not 
affected by the dietary composition or DPP-4 inhibition in 
IRS-1−/− mice (Fig. 7a, b). An SL or SO diet containing a 
DPP-4 inhibitor had no significant effects on insulin sensi-
tivity, glucose tolerance, or insulin secretion in response to 
glucose gavage (Fig. 7c–e). No significant changes in β cell 
mass or β cell proportion were observed between the SL 
and SO groups with or without a DPP-4 inhibitor in IRS-
1−/− mice (Fig. 7f–h). Accordingly, the aggravating effects 
of an SL diet might depend on hyperglycemia or β cell dys-
function, but not insulin resistance, in mice.
Discussion
Here, we established a model in which a diet rich in 
sucrose and linoleic acid induced early mortality in obese 
diabetic db/db mice. Db/db mice are a well-known model 
of obesity, diabetes, insulin resistance, β cell failure, adi-
pose tissue inflammation, diabetic complications includ-
ing heart failure, and so on [16, 17]. The extension of the 
life span is the primary goal of medical therapy for any 
disease. Therefore, our model should be a good model 
for studying the diet-induced exacerbation of life-threat-
ening disease. Short-lived SL-fed db/db mice, however, 
demonstrated glucose intolerance, insulin resistance, β 
cell failure, and adipose tissue inflammation to degrees 
similar to those of SO-fed db/db mice. Hence, the SL-
induced shortening of the life span in db/db mice was 
thought to be caused by unidentified mechanisms.
Our previous study demonstrated that an SL diet 
induced β cell apoptosis and adipose tissue inflammation in 
βGck+/− mice [7, 8]. βGck+/− mice manifested post-pran-
dial hyperglycemia caused by impaired glucose-induced 
insulin secretion and failed to proliferate β cells in response 
to insulin resistance by high-fat diet loading [27, 28]. Glu-
cokinase in β cells also plays a crucial role in the protec-
tion of β cells against ER stress-induced apoptosis through 
IRS-2 dependent and independent pathways [29]. In db/
db mice, glucokinase activation by a glucokinase activator 
improved the glycemic profiles [30]. Therefore, glucoki-
nase-mediated signals might be intact in db/db mice, and 
the function of β cell glucokinase, but not insulin resist-
ance, could contribute to SL-induced β cell failure and adi-
pose tissue inflammation. Insulin resistant IRS-1−/− mice 
demonstrated insulin secretory defects, hyperplastic islets, 
hyperinsulinemia, and normoglycemia [19, 31]. The results 
of IRS-1−/− mice fed an SL or SO in this study showed no 
significant changes in the metabolic phenotypes or β cell 
mass, indicating that insulin resistance was not the cause of 
β cell failure. Since db/db mice become obese and uncon-
trollable hyperglycemia due to the spontaneous mutation of 
leptin receptor (LepR/ObR), the β cell failure and inflamed 
adipose tissue might be derived from the dysfunction of 
LepR/ObR-signaling, and not from dietary components in 
db/db mice fed an SL or SO diet.
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Then, what is the cause of the early mortality in SL-fed 
db/db mice? Due to strict ethical regulations involving 
research animal studies, we are required to euthanize ani-
mals when they become sick or injured. The most common 
cause of death was therefore euthanization due to unknown 
disorders. The severity of myocardial ischemia and reper-
fusion injury, the development of congestive heart failure, 
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Fig. 7 No significant effects of SL or SO diet and DPP-4 inhibitor in insulin-resistant IRS-1 deficient mice. The experiments were performed in IRS-1 
deficient (IRS-1−/−) mice after 27 weeks on an SL diet, SO diet, SL + DPP-4 inhibitor (0.4 % des-fluoro-sitagliptin) diet, or SO + DPP-4 inhibitor (0.4 % 
des-fluoro-sitagliptin) diet. a Body weight gain (n = 6). b Blood glucose levels (n = 6). c Blood glucose levels during insulin tolerance test (ITT) 
(n = 6). d Blood glucose levels during oral glucose tolerance test (OGTT) (n = 6). e Serum insulin levels during OGTT (n = 6). f β cell mass (n = 6–8). 
The β cell area is shown as a proportion of the area of the entire pancreas. g Representative pancreatic sections stained with antibodies for insulin 
(green) and glucagon (red) are shown. The scale bar represent 50 μl. h Quantification of β cell mass as a proportion of the total α-cell-plus-β-cell 
mass in the islet (n = 6)
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exacerbated in db/db diabetic mice [32]. In diabetic db/db 
mice, the monocyte/endothelial interaction was acceler-
ated by an increase in the production of 12/15 lipoxygenase 
[33]. Linoleic acid is converted to arachidonic acid in many 
animal tissues, and a linoleic acid-rich SL-diet has been 
reported to increase the tissue content of arachidonic acid 
[7], which is a precursor of prostaglandins, HETEs, and leu-
kotrienes. Of note, cardiac necrosis was reportedly induced 
by the excessive loading of linoleic acid in STZ-induced 
hyperglycemic rats [34, 35]. However, a systematic review 
and meta-analysis of prospective cohort studies indicated 
that the linoleic acid intake is inversely associated with the 
cardiovascular heart disease risk in a dose–response man-
ner [36]. We also preliminarily evaluated the heart histology 
of SL- or SO-fed db/db mice in this study, but no apparent 
differences in ischemia or fibrotic lesions were observed 
(Additional file 6: Figure S5). The deficiency of LepR/ObR 
signaling in SL-fed db/db mice might participate in the early 
mortality, because insulin resistant IRS-1 knockout mice 
fed an SO or SL diet showed no abnormality in survival rate 
compared with those fed normal chow. Accordingly, further 
research is needed to clarify the mechanisms of SL-induced 
death in db/db mice.
The results of this study also showed that DPP-4 inhibition 
protected against an SL-diet-induced shortened life span in 
db/db mice. DPP-4 inhibition also ameliorated glycemic 
control, β cell loss, and adipose tissue inflammation in db/
db mice fed either an SL or SO diet. We previously reported 
that DPP-4 inhibition improved β cell loss and adipose tis-
sue inflammation without inducing any changes in fatty acid 
contents in the tissues of SL-fed diabetic mice [7, 8]. So, the 
protective effect of DPP-4 inhibition on life span in db/db 
mice was independent of alterations in fatty acid contents in 
tissues. However, although a preliminary analyses suggested 
no differences in food intake among all groups, the differ-
ences in fatty acid intake or absorption caused by diets or 
DPP-4 inhibition might exist and function as contributing 
factors. Evidence has suggested that postprandial hypergly-
cemia is an independent risk factor for all causes of death 
and cardiovascular disease [37]. The suppression of glucose 
spikes after glucose loading induced by DPP-4 inhibition 
in db/db mice might be one explanation of its protective 
effects on longevity. The improvement of cardiac function 
after myocardial infarction through a combination of DPP-4 
inhibition and G-CSF administration has been reported, 
and liraglutide was able to confer cardioprotection and a 
survival advantage after myocardial infarction [38, 39]. In 
addition to incretins, increased SDF-1α or BNP by DPP-4 
inhibition might contribute to the protection or the regen-
eration of cardiomyocytes in this study [40]. Interestingly, 
DPP-4 itself is reportedly an obesity-related adipokine that 
might worsen insulin resistance [23]. In this study, however, 
both SL- and SO-fed db/db mice showed similar DPP-4 
activities and circulating active GLP-1 levels. Furthermore, 
the efficiency of DPP-4 inhibition as measured by the DPP-4 
activity and serum active GLP-1 levels showed no signifi-
cant differences between an SL diet and an SO diet in db/
db mice. Collectively, these results suggest that an insuffi-
ciency of DPP-4 activity was not responsible for the short-
ened life span of db/db mice fed an SL diet and increase of 
SDF-1α, BNP, or other DPP-4 target factors by DPP-4 inhi-
bition might be involved in longevity of those mice. Treat-
ment with the GLP-1 receptor agonist liraglutide improved 
the decrease in the β cell mass and fatty liver independent of 
insulin secretion in β cell-specific glucokinase homozygous 
knockout mice but failed to prolong survival, and all the 
mice died within 1 week [25]. The incretin-induced incre-
ment in β cell mass and the prolonged longevity of db/db 
mice might not be related. Recently, a report suggested that 
adipose tissue inflammation increases hepatic acetyl CoA 
and causes hepatic insulin resistance through inflamma-
tory cytokine production in high-fat-diet-fed rats [41]. We 
demonstrated that DPP-4 inhibition reduced adipose tis-
sue inflammation and inflammatory cytokine expression, 
even in db/db mice. Since the adipose tissue is the largest 
endocrine organ in the body, an investigation of the inter-
organ network involving the adipose tissue before and after 
DPP-4 inhibition could be useful for determining the effects 
of DPP-4 inhibition on life span in our model.
The dose of des-fluoro-sitagliptin and MK-0626, DPP-4 
inhibitors used in this study, may be higher than a body 
weight-based dose of DPP-4 inhibitors in the clinical prac-
tice. There might be pharmacodynamic differences in the 
absorption and persistent effects of a DPP-4 inhibitor in this 
study because DPP-4 inhibitors are orally administrated, 
not mixed in diet, in the clinical practice and the absorb-
ance of lipophilic drugs are elevated by bile especially in the 
postprandial period. Thus, consideration should be given to 
the possibility that the time- and dose-dependent effects of 
DPP-4 inhibitor contributed to the outcome.
In addition to db/db mice, Zucker diabetic fatty fa/fa (ZDF) 
rats, harboring a missense mutation (fatty, fa) in the leptin 
receptor gene (Lepr/ObR), are also widely used as a model 
of obese type 2 diabetes. In previous reports, the DPP-4 
inhibitor, sitagliptin, prevented β cell dysfunction with anti-
apoptotic, anti-inflammatory, anti-oxidant, pro-angiogenic 
and pro-proliferative effects in ZDF rats [42, 43]. Sitagliptin 
also corrected the hyperglycemia, hyperlipidemia, inflam-
mation, and hypertension in ZDF rats [43]. Furthermore, the 
treatment of ZDF rats with sitagliptin also ameliorated nitro-
sative stress, inflammation and apoptosis in retinal cells, and 
prevented diabetic nephropathy progression through anti-
inflammatory and anti-apoptotic properties [44–46]. These 
protective actions of sitagliptin have important implications 
for a better understanding how DPP-4 inhibition prevented 
the early mortality in an obese diabetes model.
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Numerous studies have demonstrated that diabetes and 
obesity are related with decreased longevity in human 
[1, 47]. Prolonging the life span is the eventual aim of the 
treatment of diabetes and obesity. Our diet-induced db/db 
mice are a good model for the study of survival and lon-
gevity in obese and diabetic subjects. The effects of DPP-4 
inhibition on life span have been obscure [13–15, 19]. 
The effect of DPP4 inhibition on weight is neutral, while 
most other hypoglycemic agents increase weight gain [48]. 
Some reports have suggested that DPP-4 inhibition has 
cardioprotective effects in humans, possibly by enhanc-
ing left ventricular functions or myocardial regeneration 
[49–51]. DPP-4 inhibition improves age-related diseases, 
such as hypertension, dyslipidemia, hepatic steatosis, and 
neurodegenerative diseases. DPP-4 inhibition may have a 
protective effect on cardiovascular diseases, which are a 
major cause of mortality in patients with diabetes. Because 
the impact of DPP-4 inhibition on cardiovascular events 
in diabetic patients likely depends on each patient’s back-
ground (i.e., disease duration, age, BMI, current therapy, 
glycemic control, or complications), further examination 
of the hypothesis presented in this study in clinical studies 
focusing on DPP-4 inhibition in humans is required.
Conclusions
We created a model of nutrient-induced early lethality in 
an obese diabetic db/db mouse with a diet containing a 
combination of sucrose and linoleic acid. We also showed 
that DPP-4 inhibition ameliorated survival in those mice. 
The results of the current study demonstrate the novel 
therapeutic potential of DPP-4 inhibitors for the exten-
sion of lifespan in diabetes patients.
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Additional file 1: Table S1. Compositions of experimental diets.
Additional file 2: Figure S1. SL-diet-induced early mortality in db/db 
mice and DPP-4 inhibition reduced lethality. Survival rates of indicated 
mice in three independent cohort studies. (a) n = 12, (b) n = 8, (c) n = 
7. The db/+ and db/db mice were fed the SL diet, SO diet, SL + DPP-4 
inhibitor diet, or SO + DPP-4 inhibitor diet, as described in Fig. 2.
Additional file 3: Figure S2. Liver and epididymal fat weights in db/+ 
mice and db/db mice. The experiments were performed in db/+ or 
db/db mice fed an SL diet, SO diet, SL containing DPP-4 inhibitor (0.4% 
des-fluoro-sitagliptin) diet, or SO containing DPP-4 inhibitor diet for 8 
weeks. (left) Liver weights as a proportion of body weight (n = 5). (right) 
Epididymal fat weights as a proportion of body weight (n = 5).
Additional file 4: Figure S3. Biochemical parameters in db/+ mice and 
db/db mice. Plasma alanine aminotransferase (ALT), free fatty acid (FFA), 
total cholesterol (TChol), and triglyceride (TG) in the indicated groups of 
mice (n = 5).
Additional file 5: Figure S4. Liver triglyceride levels in db/+ mice 
and db/db mice. Concentrations of liver TG (mg/g liver) in the indicated 
groups of mice (n = 5).
Additional file 6: Figure S5. Cardiac muscle morphology in db/db 
mice. HE staining (upper) and Masson-Goldner staining (lower) of cardiac 
muscle in the indicated of mice.
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